XKR9 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the XKR9 protein, which belongs to the XK-related (XKR) family of proteins. XKR9 is believed to be involved in the regulation of membrane dynamics, particularly in processes related to cell membrane remodeling and the movement of phospholipids between the inner and outer layers of the lipid bilayer. Proteins in the XKR family are typically associated with the regulation of processes like apoptosis and cell membrane restructuring, suggesting that XKR9 plays a role in maintaining the balance between membrane stability and dynamic cellular processes that require membrane reorganization. This makes XKR9 an important regulator of cellular membrane integrity and potentially a key player in cellular responses to environmental signals that trigger membrane changes.
Inhibitors of XKR9 function by binding to specific sites on the protein, blocking its ability to participate in the processes that regulate membrane dynamics. By inhibiting XKR9, these compounds disrupt its role in phospholipid translocation, potentially affecting membrane asymmetry and cell signaling pathways dependent on proper membrane structure. This inhibition can lead to alterations in cellular functions such as cell death regulation, cell-cell communication, and other processes requiring precise membrane reorganization. As XKR9 is likely involved in maintaining the delicate balance between membrane fluidity and stability, its inhibition may result in broader consequences for cellular homeostasis. Understanding the molecular mechanisms of XKR9 inhibitors, including their binding properties and effects on membrane dynamics, is essential for uncovering how these compounds influence cellular processes and the structural organization of the lipid bilayer in various cellular contexts.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
Statins may indirectly influence XKR9 by altering cholesterol synthesis and membrane lipid composition, potentially affecting XKR9's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, a PI3K/Akt/mTOR inhibitor, could impact XKR9 indirectly through cellular signaling pathways related to membrane dynamics and protein trafficking. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine might indirectly affect XKR9 by modulating calcium signaling, which can be relevant for membrane-associated proteins. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A may indirectly affect XKR9 through its role in chromatin remodeling and gene expression, potentially impacting XKR9's expression or function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitors like Bortezomib could indirectly influence XKR9 by modulating protein degradation pathways. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine, an autophagy modulator, could have indirect implications for XKR9 through its role in cellular degradation processes. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082, an NF-κB pathway inhibitor, may indirectly impact XKR9 by affecting cellular signaling involved in inflammation and stress responses. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib might indirectly impact XKR9 by modulating JAK/STAT signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126, an inhibitor of the ERK/MAPK pathway, might indirectly affect XKR9 by influencing cell differentiation and growth pathways. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $66.00 $153.00 | 16 | |
17-AAG, an HSP90 inhibitor, could affect XKR9 indirectly by impacting protein folding and stability. | ||||||